Neuphoria Therapeutics Inc. Goodwill, Foreign Currency Translation Gain (Loss)
Neuphoria Therapeutics Inc. (NEUP) reported Goodwill, Foreign Currency Translation Gain (Loss) of -$221.61 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Income Statement › Other Income
us-gaap:GoodwillForeignCurrencyTranslationGainLoss · last filed 2026-09-18
- Neuphoria Therapeutics Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2026-06-30 was -$16.67K.
- Neuphoria Therapeutics Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2026-03-31 was -$105.60K.
- Neuphoria Therapeutics Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2025-12-31 was -$63.22K, a 112.73% decline year-over-year.
- Neuphoria Therapeutics Inc. goodwill, foreign currency translation gain (loss) for the quarter ending 2025-09-30 was -$36.13K.
- Neuphoria Therapeutics Inc. goodwill, foreign currency translation gain (loss) for fiscal 2026 was -$221.61K, a 531.08% decline from fiscal 2025.
- Neuphoria Therapeutics Inc. goodwill, foreign currency translation gain (loss) for fiscal 2025 was $51.41K, a 1133.42% increase from fiscal 2024.
- Neuphoria Therapeutics Inc. goodwill, foreign currency translation gain (loss) for fiscal 2024 was $4.17K, a 97.68% decline from fiscal 2023.
- Neuphoria Therapeutics Inc. goodwill, foreign currency translation gain (loss) for fiscal 2023 was $179.93K.
| Period end | Goodwill, Foreign Currency Translation Gain (Loss) 3 month | Goodwill, Foreign Currency Translation Gain (Loss) 6 month | Goodwill, Foreign Currency Translation Gain (Loss) 9 month | Goodwill, Foreign Currency Translation Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$16.67K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$122.27K derived: sum of 2 quarters · filed 2026-09-18 | -$185.49K derived: sum of 3 quarters · filed 2026-09-18 | -$221.61K 10-K · filed 2026-09-18 |
| 2026-03-31 | -$105.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$168.81K derived: sum of 2 quarters · filed 2026-05-15 | -$204.94K 10-Q · filed 2026-05-15 | -$392.51K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | -$63.22K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$99.34K 10-Q · filed 2026-02-17 | -$286.92K derived: sum of 3 quarters · filed 2026-09-18 | -$330.68K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | -$36.13K 10-Q · filed 2025-11-14 | -$223.70K derived: sum of 2 quarters · filed 2026-09-18 | -$267.46K derived: sum of 3 quarters · filed 2026-09-18 | $229.25K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | -$187.57K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$231.34K derived: sum of 2 quarters · filed 2026-09-18 | $265.38K derived: sum of 3 quarters · filed 2026-09-18 | $51.41K 10-K · filed 2026-09-18 |
| 2025-03-31 | -$43.77K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $452.95K derived: sum of 2 quarters · filed 2026-05-15 | $238.98K 10-Q · filed 2026-05-15 | $175.07K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $496.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | $282.75K 10-Q · filed 2026-02-17 | $218.83K derived: sum of 3 quarters · filed 2026-02-17 | $432.80K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$213.97K 10-Q · filed 2025-11-14 | -$277.88K derived: sum of 2 quarters · filed 2025-11-14 | -$63.91K derived: sum of 3 quarters · filed 2025-11-14 | -$329.29K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$63.91K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $150.06K derived: sum of 2 quarters · filed 2025-09-29 | -$115.32K derived: sum of 3 quarters · filed 2025-09-29 | $4.17K 10-K · filed 2025-09-29 |
| 2024-03-31 | $213.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-20 | -$51.41K derived: sum of 2 quarters · filed 2025-05-20 | $68.08K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | -$265.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | -$145.89K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | $119.49K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $179.93K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |